Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients ≥60 years (CALGB 9720)

被引：0

作者：

Baer, Maria R. ^{[1
]}

George, Stephen L. ^{[1
]}

Sanford, Ben L. ^{[1
]}

Bothun, Sandra M. ^{[1
]}

Mrozek, Krzysztof ^{[1
]}

O'Loughlin, Kieran L. ^{[1
]}

Kolitz, Jonathan E. ^{[1
]}

Moore, Joseph O. ^{[1
]}

Stone, Richard M. ^{[1
]}

Powell, Bayard L. ^{[1
]}

Caligiuri, Michael A. ^{[1
]}

Bloomfield, Clara D. ^{[1
]}

Larson, Richard A.

机构：

[1] Canc & Leukemia Grp B, Chicago, IL USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.296.296

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

296

引用

页码：94A / 94A

页数：1

共 50 条

[21] Infusional etoposide, daunorubicin, vincristine, and cytarabine in relapsed acute myelogenous leukemia.
Walker, B
Elkins, S
Bigelow, C
Files, J
[J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S289 - S289
[22] A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.
Attar, Eyal C.
Johnson, Jeffrey L.
Amrein, Philip C.
Lozanski, Gerard
Wadleigh, Martha
DeAngelo, Daniel J.
Kolitz, Jonathan E.
Powell, Bayard L.
Voorhees, Peter Michael
Wang, Eunice S.
Blum, William G.
Marcucci, Guido
Bloomfield, Clara D.
Moser, Barry K.
Stone, Richard M.
Larson, Richard A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[23] Outpatient Administration of Liposomal Daunorubicin and Cytarabine (Vyxeos) in Patients With Secondary Acute Myeloid Leukemia
Kasner, Margaret T.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 604 - 606
[24] Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
Chen, Evan C.
Fathi, Amir T.
Brunner, Andrew M.
[J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3425 - 3434
[25] Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
Bewersdorf, Jan Philipp
Goshua, George
Patel, Kishan K.
Shallis, Rory M.
Podoltsev, Nikolai
Huntington, Scott F.
Zeidan, Amer M.
[J]. BLOOD, 2021, 138
[26] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
Ramanathan, Muthalagu
Cerny, Jan
Raffel, Glen
Walsh, William Vincent
Woda, Bruce
Miron, Patricia
Nath, Rajneesh
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[27] Interaction Outcomes of Cytarabine-Daunorubicin Combination during Acute Myeloid Leukemia Chemotherapy: An In Silico Study
Wang, Fang
Liu, Yujuan
Song, Shuangxiu
Wang, Fang
Li, Zhaoxia
[J]. LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (04): : 663 - 669
[28] Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients ≥ 60 years old:: Correlation of outcome with functional MDR (CALGB studies 9720 and 9760).
Baer, MR
George, SL
Dodge, RK
O'Loughlin, KL
Minderman, H
Caligiuri, MA
Anastasi, J
Powell, BL
Kolitz, JE
Schiffer, CA
Bloomfield, CD
Larson, RA
[J]. BLOOD, 2001, 98 (11) : 461A - 462A
[29] GM-CSF to increase efficacy of mitoxantrone, etoposide and cytarabine (MEA) in previously untreated patients (> 60 years) with acute myeloid leukemia (AML):: A Swedish multicenter randomized trial.
Löfgren, C
Paul, C
Åström, M
Liliemark, J
Nilsson, I
Stockelberg, D
Rödjer, S
Tidefelt, U
Björkholm, M
[J]. BLOOD, 2002, 100 (11) : 344A - 345A
[30] Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Faderl, S
Verstovsek, S
Cortes, J
Ravandi, F
Beran, M
Garcia-Manero, G
Ferrajoli, A
Estrov, Z
O'Brien, S
Koller, C
Giles, FJ
Wierda, W
Kwari, M
Kantarjian, HM
[J]. BLOOD, 2006, 108 (01) : 45 - 51

← 1 2 3 4 5 →